Peter Oppelt

Washington University in St. Louis

Papers

1

Total Citations

5

H-Index

1

About

Dr. Peter Oppelt is a leading oncologist whose research focuses on optimizing treatment for human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), a cancer with rising incidence. His major contribution lies in pioneering de-escalation strategies to reduce long-term toxicity without compromising survival. In his landmark non-randomized, multi-arm Phase 2 trial (2024), he demonstrated that risk-directed, de-escalated adjuvant therapy after surgery yields durable efficacy, sparing patients from aggressive radiation and chemotherapy side effects. This work, already cited 5 times, has reshaped clinical paradigms by proving that less can be more in HPV-driven cancers. Dr. Oppelt’s research integrates precision medicine with quality-of-life outcomes, earning him recognition as a thought leader in head and neck oncology. His findings are pivotal for young researchers exploring biomarker-driven treatment de-intensification, offering a model for balancing cure with survivorship. Through rigorous trial design and patient-centered endpoints, he continues to advance personalized cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial
5 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Washington University in St. Louis

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago